NCT06757283View on ClinicalTrials.gov

ZyVac-TCV Bangladesh Study

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

4,000

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

May 30, 2026

Conditions
Typhoid VaccinationTyphoidTyphoid Fever
Interventions
BIOLOGICAL

Purified Vi capsular polysaccharide of Salmonella typhi conjugated to tetanus toxoid as carrier protein (Typhoid Vi Conjugate Vaccine I.P.). Trade name: ZyVac® TCV

Purified Vi capsular polysaccharide of Salmonella typhi conjugated to tetanus toxoid as carrier protein (Typhoid Vi Conjugate Vaccine I.P.)

Trial Locations (1)

Unknown

International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka

All Listed Sponsors
collaborator

Zydus Lifesciences Limited

INDUSTRY

lead

International Centre for Diarrhoeal Disease Research, Bangladesh

OTHER